Ameriprise’s Nektar Therapeutics NKTR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $9.84M | Buy |
+136,730
| New | +$7.79M | ﹤0.01% | 1936 |
|
|
2025
Q2 | – | Sell |
-20,629
| Closed | -$210K | – | 4075 |
|
|
2025
Q1 | $210K | Sell |
20,629
-4,301
| -17% | -$56.2K | ﹤0.01% | 3774 |
|
|
2024
Q4 | $348K | Buy |
24,930
+6,157
| +33% | +$109K | ﹤0.01% | 3662 |
|
|
2024
Q3 | $366K | Sell |
18,773
-689
| -4% | -$13.1K | ﹤0.01% | 3586 |
|
|
2024
Q2 | $362K | Buy |
19,462
+4,756
| +32% | +$100K | ﹤0.01% | 3540 |
|
|
2024
Q1 | $206K | Sell |
14,706
-15,433
| -51% | -$162K | ﹤0.01% | 3683 |
|
|
2023
Q4 | $255K | Sell |
30,139
-2,421
| -7% | -$18.3K | ﹤0.01% | 3655 |
|
|
2023
Q3 | $291K | Sell |
32,560
-133
| -0.4% | -$1.28K | ﹤0.01% | 3592 |
|
|
2023
Q2 | $282K | Sell |
32,693
-33,598
| -51% | -$358K | ﹤0.01% | 3627 |
|
|
2023
Q1 | $699K | Buy |
66,291
+6,761
| +11% | +$205K | ﹤0.01% | 3302 |
|
|
2022
Q4 | $2.02M | Buy |
59,530
+6,595
| +12% | +$319K | ﹤0.01% | 2805 |
|
|
2022
Q3 | $2.54M | Buy |
52,935
+1,940
| +4% | +$115K | ﹤0.01% | 2675 |
|
|
2022
Q2 | $2.91M | Sell |
50,995
-1,066
| -2% | -$67.3K | ﹤0.01% | 2635 |
|
|
2022
Q1 | $4.21M | Sell |
52,061
-1,252
| -2% | -$185K | ﹤0.01% | 2533 |
|
|
2021
Q4 | $10.8M | Buy |
53,313
+34,973
| +191% | +$7.59M | ﹤0.01% | 1929 |
|
|
2021
Q3 | $4.94M | Sell |
18,340
-925
| -5% | -$222K | ﹤0.01% | 2394 |
|
|
2021
Q2 | $4.96M | Sell |
19,265
-111,818
| -85% | -$30.9M | ﹤0.01% | 2464 |
|
|
2021
Q1 | $39.3M | Buy |
131,083
+110,506
| +537% | +$34.4M | 0.01% | 887 |
|
|
2020
Q4 | $5.25M | Sell |
20,577
-1,230
| -6% | -$318K | ﹤0.01% | 2239 |
|
|
2020
Q3 | $5.43M | Sell |
21,807
-1,344
| -6% | -$423K | ﹤0.01% | 2011 |
|
|
2020
Q2 | $8.04M | Sell |
23,151
-420
| -2% | -$131K | ﹤0.01% | 1695 |
|
|
2020
Q1 | $6.31M | Sell |
23,571
-1,895
| -7% | -$586K | ﹤0.01% | 1738 |
|
|
2019
Q4 | $8.24M | Buy |
25,466
+20,658
| +430% | +$5.99M | ﹤0.01% | 1903 |
|
|
2019
Q3 | $1.31M | Buy |
4,808
+923
| +24% | +$338K | ﹤0.01% | 2893 |
|
|
2019
Q2 | $2.07M | Sell |
3,885
-1,531
| -28% | -$768K | ﹤0.01% | 2733 |
|
|
2019
Q1 | $2.73M | Buy |
5,416
+720
| +15% | +$427K | ﹤0.01% | 2589 |
|
|
2018
Q4 | $2.31M | Sell |
4,696
-983
| -17% | -$593K | ﹤0.01% | 2590 |
|
|
2018
Q3 | $5.19M | Buy |
5,679
+596
| +12% | +$509K | ﹤0.01% | 2317 |
|
|
2018
Q2 | $3.66M | Sell |
5,083
-2,840
| -36% | -$3.27M | ﹤0.01% | 2449 |
|
|
2018
Q1 | $12.6M | Sell |
7,923
-51,975
| -87% | -$67M | 0.01% | 1477 |
|
|
2017
Q4 | $53.7M | Sell |
59,898
-3,094
| -5% | -$1.83M | 0.02% | 558 |
|
|
2017
Q3 | $22.7M | Sell |
62,992
-504
| -0.8% | -$158K | 0.01% | 966 |
|
|
2017
Q2 | $18.6M | Buy |
63,496
+5,300
| +9% | +$1.53M | 0.01% | 1076 |
|
|
2017
Q1 | $20.5M | Buy |
58,196
+7,027
| +14% | +$1.58M | 0.01% | 1001 |
|
|
2016
Q4 | $9.42M | Buy |
51,169
+5,803
| +13% | +$1.18M | 0.01% | 1579 |
|
|
2016
Q3 | $11.7M | Buy |
45,366
+1,435
| +3% | +$369K | 0.01% | 1329 |
|
|
2016
Q2 | $9.38M | Buy |
43,931
+1,695
| +4% | +$379K | 0.01% | 1442 |
|
|
2016
Q1 | $8.71M | Buy |
42,236
+1,161
| +3% | +$223K | 0.01% | 1536 |
|
|
2015
Q4 | $10.4M | Sell |
41,075
-421
| -1% | -$86.6K | 0.01% | 1419 |
|
|
2015
Q3 | $6.82M | Buy |
41,496
+234
| +0.6% | +$41.4K | ﹤0.01% | 1766 |
|
|
2015
Q2 | $7.74M | Buy |
41,262
+37,665
| +1,047% | +$6.48M | ﹤0.01% | 1804 |
|
|
2015
Q1 | $593K | Buy |
3,597
+1,890
| +111% | +$388K | ﹤0.01% | 3131 |
|
|
2014
Q4 | $397K | Buy |
1,707
+1,109
| +185% | +$237K | ﹤0.01% | 3210 |
|
|
2014
Q3 | $109K | Sell |
598
-419
| -41% | -$80.2K | ﹤0.01% | 3641 |
|
|
2014
Q2 | $195K | Buy |
1,017
+861
| +552% | +$152K | ﹤0.01% | 3334 |
|
|
2014
Q1 | $29K | Buy |
156
+20
| +15% | +$3.96K | ﹤0.01% | 4029 |
|
|
2013
Q4 | $23K | Sell |
136
-494
| -78% | -$79.7K | ﹤0.01% | 4000 |
|
|
2013
Q3 | $98K | Hold |
630
| – | – | ﹤0.01% | 3472 |
|
|
2013
Q2 | $109K | Buy |
+630
| New | +$96.6K | ﹤0.01% | 3341 |
|
Other funds holding NKTR
BI
TSC
VCM
PM
AC
Ameriprise's NKTR Position: Q1 2026 in Review
Ameriprise opened a new position in Nektar Therapeutics (NKTR) in Q1 2026: 136,730 shares worth $9.84M. The stake represents ﹤0.01% of the portfolio and ranks #1936 among its holdings. This is a return to the name: Ameriprise previously reported a position in NKTR as recently as Q1 2025.
Ameriprise first reported a position in NKTR in Q2 2013 and has held it in 49 quarters since. The position peaked at $53.7M in Q4 2017. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.
- Ameriprise held 136,730 shares of Nektar Therapeutics worth $9.84M as of Q1 2026.
- Nektar Therapeutics was a new Ameriprise position in Q1 2026.
- Nektar Therapeutics made up ﹤0.01% of Ameriprise's portfolio in Q1 2026, its #1936 holding.
- Ameriprise first reported a position in Nektar Therapeutics in Q2 2013 and has held it in 49 quarters since.
- Ameriprise's Nektar Therapeutics position peaked at $53.7M in Q4 2017.
- 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.
Based on Ameriprise's 13F filing for Q1 2026, filed 15 May 2026.